Małgorzata Janeczko-Czarnecka

Dr. Małgorzata Janeczko-Czarnecka


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2016 in Central European Journal of Immunology
Verified
Journal Article
Open access
MJMałgorzata Janeczko-Czarnecka
Małgorzata Janeczko-Czarnecka
MMMonika Mielcarek
Monika Mielcarek
BRBlanka Rybka
Blanka Rybka
RRRenata Ryczan-Krawczyk
Renata Ryczan-Krawczyk
DNDorota Noworolska-Sauren
Dorota Noworolska-Sauren
KKKrzysztof Kałwak
Krzysztof Kałwak
Immune reconstitution was studied prospectively in 86 children who underwent allogeneic haematopoietic stem cell transplantation (HSCT). We analysed the risk of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation in correlation with the kinetics of immune recovery and in relation to other potential risk factors that may influence the reactivation of these viruses including: diagnosis, type of HSCT, source of stem cells, type of conditioning, or the occurrence of graft-versus-host disease (GvHD). The absolute number of lymphocyte subpopulations in peripheral blood was evaluated in seven timepoints following HSCT. Significantly lower values of both CD3+ and CD3+CD8+ lymphocytes on day +14 and significantly higher values of both these subsets on day +168 post-transplant in patients with CMV reactivation were observed. Significantly lower values of CD3+CD4+ subpopulation were noted in patients with CMV reactivation on day +28 post allo-HSCT. Significantly lower lymphocyte values in the group with EBV reactivation comparing with the group without EBV reactivation were confirmed only in the case of pan-B lymphocytes (CD19+) subpopulation on day +21, +28, and +84 post allo-HSCT. We identified the impact of CMV reactivation on occurrence of the intestinal acute GvHD, which occurred more frequently in the group with CMV reactivation compared with patients without reactivation. Higher incidence of chronic GvHD was also observed in patients with CMV reactivation compared to the group without reactivation. EBV reactivation occurred more frequently in patients receiving transplants from matched unrelated donors, in particular after peripheral blood stem cell transplantation and while implementing antithymocyte globulin as GvHD prophylaxis.

26 February 2020 in Central European Journal of Immunology
Verified
Journal Article
Open access
MJMałgorzata Janeczko-Czarnecka
Małgorzata Janeczko-Czarnecka
BRBlanka Rybka
Blanka Rybka
RRRenata Ryczan-Krawczyk
Renata Ryczan-Krawczyk
KKKrzysztof Kałwak
Krzysztof Kałwak
Marek UssowiczMarek Ussowicz
Marek Ussowicz
Thymic output was studied prospectively in 52 children who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thymic activity was assessed by quantification of recent thymic emigrants (RTE) discriminated from the rest of naive T cells by immunophenotype CD3+/CD4+/CD31+/CD45RA+. Thymic output was analyzed in correlation with the kinetics of immune recovery and in relation to other potential risk factors that may influence thymopoiesis: underlying disease, type of HSCT, source of stem cells, age of recipient and donor, type of conditioning, implemented graft versus host disease (GvHD) prophylaxis, viral reactivations (herpes viruses cytomegalovirus – CMV, Epstein-Barr virus – EBV, adenovirus – ADV, BK virus – BKV), occurrence and grade of both acute and chronic graft versus host disease (aGvHD, cGvHD) and number of transplanted CD34 cells/kg. The absolute count of RTE in peripheral blood was evaluated at 6 time points: before the conditioning and on days +15, +30, +60, +90 and +180 after HSCT. Occurrence of grade II-IV aGvHD was the most important factor associated with low RTE counts after HSCT. History of malignant disease, and transplantation from matched unrelated donor were risk factors for lower thymic output. We found a weak inverse correlation between the age of the recipient and thymic output on post-HSCT day +180. Source of stem cells, type of conditioning, viral reactivations, occurrence of chronic GvHD, age of the donor and the number of transplanted CD34 cells/kg did not affect thymopoiesis in our study group. These preliminary findings and identification of risk factors for deterioration of thymic activity may in the future help in selecting candidates for thymus rejuvenation strategies.

26 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMałgorzata Salamonowicz-Bodzioch
Małgorzata Salamonowicz-Bodzioch
MRMonika Rosa
Monika Rosa
JFJowita Frączkiewicz
Jowita Frączkiewicz
EGEwa Gorczyńska
Ewa Gorczyńska
KGKatarzyna Gul
Katarzyna Gul
Marek UssowiczMarek Ussowicz
Marek Ussowicz
Severe aplastic anemia (SAA) is a bone marrow failure syndrome that can be treated with hematopoietic cell transplantation (HCT) or immunosuppressive (IS) therapy. A retrospective cohort of 56 children with SAA undergoing transplantation with fludarabine–cyclophosphamide–ATG-based conditioning (FluCyATG) was analyzed. The endpoints were overall survival (OS), event-free survival (EFS), cumulative incidence (CI) of graft versus host disease (GVHD) and CI of viral replication. Engraftment was achieved in 53/56 patients, and four patients died (two due to fungal infection, and two of neuroinfection). The median time to neutrophil engraftment was 14 days and to platelet engraftment was 16 days, and median donor chimerism was above 98%. The overall incidence of acute GVHD was 41.5%, and that of grade III-IV acute GVHD was 14.3%. Chronic GVHD was diagnosed in 14.2% of children. The probability of 2-year GVHD-free survival was 76.1%. In the univariate analysis, a higher dose of cyclophosphamide and previous IS therapy were significant risk factors for worse overall survival. Episodes of viral replication occurred in 33/56 (58.9%) patients, but did not influence OS. The main advantages of FluCyATG include early engraftment with a very high level of donor chimerism, high overall survival and a low risk of viral replication after HCT.

1 November 2019 in Transplantation Proceedings
Verified
Journal Article
Closed access
MJMałgorzata Janeczko-Czarnecka
Małgorzata Janeczko-Czarnecka
KKKrzysztof Kałwak
Krzysztof Kałwak
Marek UssowiczMarek Ussowicz
Marek Ussowicz

16 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
MJMałgorzata Janeczko-Czarnecka
Małgorzata Janeczko-Czarnecka
MGMaciej Gręda
Maciej Gręda
DCDorota Cichosz
Dorota Cichosz
RŚRobert Śmigiel
Robert Śmigiel
MBMateusz Biela
Mateusz Biela
PLA2G6-associated neurodegeneration (PLAN) is an autosomal recessive neurodegenerative spectrum encompassing infantile, juvenile/atypical and adult-onset phenotypes. Juvenile PLAN may initially resemble autism spectrum disorder or nonspecific developmental regression, delaying diagnosis. We describe a 14-year-old boy and his 9-year-old sister, both with initially normal early development, followed by progressive gait impairment, speech and cognitive regression, epilepsy or paroxysmal events, contractures and loss of independent ambulation. Brain MRI in both siblings demonstrated marked symmetric cerebellar atrophy, susceptibility-weighted hypointensity of the globus pallidus and substantia nigra compatible with iron accumulation and bilateral optic nerve thinning. Electroneurography showed selective motor axonal involvement. Molecular testing identified the same two heterozygous PLA2G6 findings in both children: c.1934G>A (p.Arg645Gln), classified as likely pathogenic by the diagnostic laboratory, and a copy-number gain encompassing exons 4–7. Parental testing was unavailable; therefore, the phase of the findings could not be established, and it remains unknown whether they are in trans or in cis. The shared phenotype is highly suggestive of juvenile PLAN. However, unresolved phase and incomplete structural characterization of the copy-number gain preclude confirmation of biallelic PLA2G6 involvement and definitive molecular attribution. These related cases provide a descriptive account of a juvenile PLAN-like phenotype, without independently attributing the phenotype to p.Arg645Gln, establishing variant pathogenicity or a specific genotype–phenotype correlation.

18 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MJMałgorzata Janeczko-Czarnecka
Małgorzata Janeczko-Czarnecka
MGMaciej Gręda
Maciej Gręda
DCDorota Cichosz
Dorota Cichosz
RŚRobert Śmigiel
Robert Śmigiel
MBMateusz Biela
Mateusz Biela
Background/Objectives: PLA2G6-associated neurodegeneration (PLAN) is an autosomal recessive neurodegenerative spectrum encompassing infantile, juvenile/atypical, and adult-onset phenotypes. Juvenile PLAN may initially resemble autism spectrum disorder or nonspecific developmental regression, delaying diagnosis. Case Presentation: We describe a 14-year-old boy and his 9-year-old sister, both with initially normal early development followed by progressive gait impairment, speech and cognitive regression, epilepsy, contractures, and loss of independent ambulation. Brain MRI in both siblings demonstrated marked symmetric cerebellar atrophy, susceptibility-weighted hypointensity of the globus pallidus and substantia nigra compatible with iron accumulation, and bilateral optic nerve thinning. Electroneurography showed selective motor axonal involvement. Molecular testing identified the same two heterozygous PLA2G6 findings in both children: c.1934G>A (p.Arg645Gln) and an exon 4–7 copy-number gain. Parental testing was unavailable; therefore, the phase of the findings could not be established, and it remains unknown whether they are in trans or in cis. Conclusions: The shared clinical, neuroimaging, and electrophysiological phenotype is strongly consistent with juvenile PLAN and provides additional phenotypic evidence regarding p.Arg645Gln. However, unresolved phase and incomplete structural characterization of the copy-number gain preclude definitive molecular attribution. These cases emphasize the diagnostic value of susceptibility-weighted MRI, deletion/duplication analysis, and family segregation studies in children with progressive neurodevelopmental regression.